Rare lephants
Screener

Nuo Therapeutics, Inc.

AURX ·Healthcare, Medical Devices, United States
Analysis › Moat Score

Moat Score — Nuo Therapeutics, Inc.

Total Moat Score 6 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 3 / 5 Holds FDA 510(k) clearance since 2007 for its Aurix PRP system plus a dedicated CMS National Coverage Determination for reimbursement — real regulatory assets that raise the bar for new entrants.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 0 / 5 As a roughly 10-employee company it has no manufacturing or purchasing scale advantage versus much larger wound-care competitors like 3M or ConvaTec.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 1 / 5 CMS sets fixed reimbursement rates for the PRP treatment category, limiting Nuo's own pricing flexibility, though having a dedicated coverage code is itself a modest advantage over uncovered alternatives.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 No network effect dynamics exist in a point-of-care medical device sold through independent sales representatives.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 1 / 5 Clinician training and workflow integration for point-of-care blood processing create mild switching friction once a provider adopts the Aurix system.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 1 / 5 The autologous PRP wound-care niche with a dedicated Medicare NCD is narrow enough that it may not support many directly competing dedicated-technology entrants, though Nuo now faces its own distribution partner's private-label version.